CGRP vs Dalargin

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.

Dalargin (D-Ala2-Leu5-Arg6-enkephalin) is a synthetic hexapeptide opioid receptor agonist developed in the Soviet Union as a stable enkephalin analog, designed with D-amino acid substitution to resist enzymatic degradation, and investigated for gastroprotective and analgesic properties in animal models and limited Russian clinical use. Dalargin binds mu and delta opioid receptors and is proposed to exert gastroprotective effects through opioid receptor-mediated suppression of gastric acid secretion, stimulation of mucosal prostaglandin synthesis, and promotion of epithelial repair, with additional central analgesic activity demonstrated in preclinical studies. Published evidence in Western PubMed-indexed journals is limited to animal studies demonstrating gastroprotective activity against NSAID-induced mucosal damage; the compound has been used in Russian clinical practice for peptic ulcer disease, but no randomized controlled trials meeting current methodological standards have been published in English-language indexed journals. Dalargin has no FDA approval and no regulatory approval in any Western jurisdiction; it is an obscure research compound whose evidence base is largely confined to Soviet-era and Russian-language literature, and its safety and efficacy profile in humans has not been validated by independent clinical investigation.